No known allergy to aspirin Patients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumab Known allergy to boron or excipients in the formulation Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos) Patients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy Known allergy to any of the study agents Known allergy to enadenotucirev, nivolumab or their excipients Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT- Prior allergy or adverse reaction to methotrexate No known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG) Patients with a latex allergy Known in tolerance and allergy to cytarabine. Known allergy to grapes or grape seed Bovine product allergy Known or suspected allergy or hypersensitivity to the study drug Allergy to measles vaccine or history of severe reaction to prior measles vaccination Allergy to shellfish Milk allergy Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. . Known history of contrast allergy that cannot be medically managed EXCLUSION - TREATMENT: Known allergy to VZV vaccine Known allergy to HCQ Patients with known allergy or hypersensitivity to AG or venetoclax. Doxycycline allergy Known allergy to PEGylated products Participants must not have a history of allergy to nivolumab, urelumab or cabiralizumab Bupivacaine or liposomal bupivacaine sensitive or known allergy. Known allergy to anthracyclines. Allergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen History of allergy to merestinib or chemically related compounds Patient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluents Known allergy or hypersensitivity to IP Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty Known allergy to grapes or grape seed Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialist Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy Patients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excluded Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded Known allergy to coenzyme Q Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K Known allergy to doxycycline or tetracycline Known allergy to ODM- or any of the excipients. Known or suspected allergy to lenvatinib or any agent given in the course of this trial History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccine Known allergy to PIO Allergy to measles vaccine or history of severe reaction to prior measles vaccination Allergy to lidocaine, fentanyl, midazolam, or propofol (may be used during tumor biopsy or injection) Allergy or hypersensitivity to agents used within the treatment protocol Patients who have known allergy to mebendazole DONOR: Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test products Patients with known allergy to bovine or murine products Patients with known carboplatin or cisplatin allergy Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product. Known allergy to sulfa or specific allergy to sulfonylurea drugs Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol Patients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditions Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty Allergy to filgrastim, pegfilgrastim, or loratadine Patients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test) Patient does not have known allergy to polyethylene glycol hydrogel (spacer material) Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty Gold allergy Known history of allergy to Captisol Known or suspected allergy or hypersensitivity to sorafenib Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty Patients with a known history of allergy to soy products MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum Allergy to measles vaccine or history of severe reaction to prior measles vaccination Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol History of allergy to penicillin or related antibiotic Patients with an allergy or known hypersensitivity to fish Known allergy to any of the agents or their ingredients used in this study Allergy to oseltamivir or excipients Known allergy to domperidone Known or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trial Patients with latex allergy. Patients who have an allergy to gold. Corn allergy History of allergy to KLH, QS-, OPT-, or glucan Patient having known allergy to NSAID or Aspirin Known allergy to doxorubicin or anthracyclines. History of allergy or hypersensitivity to the device constituent or Inserter materials. Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium; Patients with known allergy to bovine or murine products. Patients with known allergy to MB Known allergy(ies) to any component of CMB or LV. Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty. Allergy to measles vaccine or history of severe reaction to prior measles vaccination Known allergy to hyaluronidase Allergy to measles vaccine or history of severe reaction to prior measles vaccination Allergy to measles vaccine or history of severe reaction to prior measles vaccination DONOR: Known allergy to filgrastim (GCSF) Allergy to measles vaccine or history of severe reaction to prior measles vaccination Known history of allergy to Captisol Soy allergy History of allergy or untoward reaction to prior vaccination with vaccinia virus Known history of positive serum human ADA, or known allergy to any component of ADCT-. Known allergy(ies) to any component of CMB or CPA Patients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergy Known allergy to boron, MLN, any of the study treatments, their analogues, or excipients. Known allergy to both penicillin and sulfa antibiotics No known allergy to platinum compounds Known or suspected allergy to any agent given in the course of this trial Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin. Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty Known or suspected allergy to sorafenib or any agent given in the course of this trial Have a known allergy to tomatoes or have never consumed tomatoes Known allergy to thalidomide. Allergy to ganciclovir or acyclovir Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent; Patient has a history of allergy to red color food dye. Known allergy to hyaluronidase Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR) Known allergy or hypersensitivity to Investigational Product. Patients with documented allergy to cephalosporins Patient has a known allergy to both penicillin and sulfa All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccine Known or suspected allergy to sorafenib or any agent given in the course of this trial Known history of allergy to Captisol Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy Known allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.) Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine Known or suspected allergy to gemcitabine or MLN, or any agent given in the course of this trial Known or suspected allergy to irinotecan or MLN, or any agent given in the course of this trial Known allergy to any of the study medications A known allergy to any component of the HyperAcute-Lung immunotherapy or cell lines from which it is derived. Patients who have known allergy to mebendazole or benzimidazole Allergy or hypersensitivity to agents used within the treatment protocol Known allergy to any of the compounds under investigation Medically diagnosed lactose intolerance, lactose allergy or salicylate allergy If patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > . Fahrenheit [F]/. Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class or ) or known lung (forced expiratory volume in second [FEV] < %) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergy Known or suspected allergy to pazopanib Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate. History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy Known or suspected allergy to ARQ Patients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride) Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy. Patients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin. Known or suspected allergy to sorafenib (BAY -) or any agent given in association with this trial DONOR: Known allergy to G-CSF Patients will be excluded if they have a known allergy to any of the drugs used in the study Allergy to measles vaccine or history of severe reaction to prior measles vaccination. Known allergy to bone cement, Patients will be excluded if they have a known allergy to any of the drugs used in the study. Any known allergy to the compounds under investigation Patients with known allergy or hypersensitivity to IMGN Known allergy to wheat, rice (contained in the placebo), orange or the sweetener, Stevis Known allergy to hyaluronidase or any constituents of docetaxel formulation. Bovine product allergy Known allergy to any of the study drugs Known allergy to BCG or MMC Prior history of penicillin or streptomycin allergy Patients with a soy allergy will be excluded Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat) The subject has a known allergy to tetracycline Known allergy to macrolide antibiotics Known allergy to any of the study agents Allergy to either of the study medications or -fluorouracil Nut allergy Patient has a known allergy to bovine or porcine products. Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane. Has no known allergy to murine products or positive HAMA Known allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement) Allergy to implant materials or dental glue. Known allergy to treatment medication (vemurafenib) Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product. Known allergy to study medications History of significant drug-related allergy (such as anaphylaxis) Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related compounds Known allergy to doxycycline or other tetracycline antibiotics History of allergy to Urelumab (BMS-) or related compounds History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy Known allergy to any of the study medications Known or suspected allergy to sorafenib Known or suspected allergy to sorafenib or any agent given in the course of this trial Known or suspected allergy to any agent given in the course of this trial Allergy: known hypersensitivity to other recombinant human antibodies Patients with known systemic allergy to bovine or murine products Known allergy to any of the agents or their ingredients used in this study Allergy to bupropion Known allergy to adhesive tape Known or suspected allergy to pamidronate or related products Known allergy to EACA Allergy to allopurinol known allergy to both penicillin and sulfa drugs Known allergy to soy or any soy-based food or supplement Known allergy to local anesthetics Known allergy to perampanel History of an allergy to romiplostim History of allergy to fentanyl Allergy treatment with antigen injections Known true tape allergy No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder) Known allergy to stevia Allergy treatment with antigens injections Patients with a known allergy or hypersensitivity to CHG are ineligible Patients with an allergy to quinolones Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo Known allergy to a probiotic preparation Food allergy to any component of the supplement History of allergy to investigational agent: ropivacaine or other amino amide analgesics History of allergy to standard agent: propofol Allergy to fentanyl Allergy to gabapentin No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms Antibiotic allergy to study medication Allergy to bone morphogenetic protein Allergy to bovine collagen products Patients with documented allergy to soy products. Allergy to beef History of allergy to fentanyl History of allergy to fentanyl Participant has a known allergy to melatonin or any ingredients of the study product or placebo Patients must not have an allergy to latex Patients with history of allergy or adverse reactions to sodium bicarbonate or normal saline No known allergy to either ACE inhibitors or ?-blockers Known allergy to phenylephrine Doxycycline allergy Allergy to gabapentin Allergy to either Eucerin or MF Known allergy or preexisting skin disease which prohibits use of menthol Known allergy to a probiotic preparation History of allergy to acetic acid No allergy to finasteride or other five alpha reductase inhibitors History of allergy to apixaban or Factor Xa inhibitors History of any significant drug allergy (such as anaphylaxis or hepatotoxicity Known allergy to electrode adhesives or woven knit compression fabrics RECIPIENT: Allergy treatment with antigens injections Known allergy to LCM or LEV Known history of allergy to any component or other contraindications to any Neurokinin- (NK) or -hydroxytryptamine (-HT) receptor antagonists. Individuals with a known allergy to lidocaine are not eligible Women with an allergy to rapamycin or its derivatives Documented allergy to apixaban and/or enoxaparin Allergy to nicotine patch, nicotine lozenge, or varenicline Patient has allergy to fish or is a vegetarian Bovine product allergy. Subjects with a known allergy to lidocaine Patients with an allergy to Peridex/chlorhexidine solution Has a history of significant allergy to calcitriol as determined by the investigator. Has known allergy to Tcm sestamibi Iodide or seafood allergy Women with a known allergy to proflavine or acriflavine Known allergy to adhesive tapes or other skin adhesives used in medical care Allergy to sulfa or sulfa-containing medications Allergy to sulfa or sulfa-containing medications History of allergy to iodide drugs or shellfish (iodine allergy) Prior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is noted Patients with a known allergy to Benadryl Subjects with established allergy to IV GBCA Patients with history of allergy to hydrogel dressing or ongoing skin diseases Has known allergy to Tc m sestamibi Women with a known allergy to proflavine or acriflavine Patients with allergy to regadenoson Known allergy or anaphylactic reaction to indocyanine green (ICG). Severe food or medication allergy Known allergy to proflavine or acriflavine History of multiple food and/or drug allergy Has a known allergy to dextran or VBD (if intended to be used) History of any anaphylactic reaction, any severe allergy, or any allergy to folate Has a known allergy to dextran Known allergy to FdCyd Allergy to fluoroquinolones Allergy to Brussels sprouts Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy Nut or seed allergy No known allergy to tree nuts Participant must not have a history of allergy to erlotinib